125 related articles for article (PubMed ID: 12232712)
1. [F-18 FDG positron emission tomography in diagnosis and follow-up of patients with musculoskeletal tumors].
Dobrowolskij D; Niggemeyer O; Jenicke L; Bruns J
Orthopade; 2002 Sep; 31(9):921-9. PubMed ID: 12232712
[TBL] [Abstract][Full Text] [Related]
2. The clinical efficacy of (18)F-FDG-PET/CT in benign and malignant musculoskeletal tumors.
Shin DS; Shon OJ; Han DS; Choi JH; Chun KA; Cho IH
Ann Nucl Med; 2008 Aug; 22(7):603-9. PubMed ID: 18756363
[TBL] [Abstract][Full Text] [Related]
3. Monitoring bone and soft-tissue tumors after carbon-ion radiotherapy using ¹⁸F-FDG positron emission tomography: a retrospective cohort study.
Yanagawa T; Saito K; Kiyohara H; Ohno T; Nakano T; Takagishi K
Radiat Oncol; 2015 Dec; 10():259. PubMed ID: 26691334
[TBL] [Abstract][Full Text] [Related]
4. Role of repeated F-18 fluorodeoxyglucose imaging in management of patients with bone and soft tissue sarcoma.
el-Zeftawy H; Heiba SI; Jana S; Rosen G; Salem S; Santiago JF; Abdel-Dayem HM
Cancer Biother Radiopharm; 2001 Feb; 16(1):37-46. PubMed ID: 11279796
[TBL] [Abstract][Full Text] [Related]
5. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of fluorodeoxyglucose positron emission tomography in the management of soft-tissue sarcomas.
Lucas JD; O'Doherty MJ; Wong JC; Bingham JB; McKee PH; Fletcher CD; Smith MA
J Bone Joint Surg Br; 1998 May; 80(3):441-7. PubMed ID: 9619933
[TBL] [Abstract][Full Text] [Related]
7. A comparative study of F-18 FDG PET and 201Tl scintigraphy for detection of primary malignant bone and soft-tissue tumors.
Yamamoto Y; Kawaguchi Y; Kawase Y; Maeda Y; Nishiyama Y
Clin Nucl Med; 2011 Apr; 36(4):290-4. PubMed ID: 21368603
[TBL] [Abstract][Full Text] [Related]
8. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy.
Schuetze SM; Rubin BP; Vernon C; Hawkins DS; Bruckner JD; Conrad EU; Eary JF
Cancer; 2005 Jan; 103(2):339-48. PubMed ID: 15578712
[TBL] [Abstract][Full Text] [Related]
9. [Diagnosis with (18)F-FDG PET scan after larynx preservation by primary radiochemotherapy].
Dietz A; Rudat V; Harms W; Jungehülsing M; Dollner R; Henze M
HNO; 2004 Jan; 52(1):38-44. PubMed ID: 14740113
[TBL] [Abstract][Full Text] [Related]
10. Prospective comparison of 18F-FDG PET with conventional imaging modalities (MRI, CT, and 67Ga scintigraphy) in assessment of combined intraarterial chemotherapy and radiotherapy for head and neck carcinoma.
Kitagawa Y; Nishizawa S; Sano K; Ogasawara T; Nakamura M; Sadato N; Yoshida M; Yonekura Y
J Nucl Med; 2003 Feb; 44(2):198-206. PubMed ID: 12571209
[TBL] [Abstract][Full Text] [Related]
11. F-18 FDG PET and PET/CT evaluation of response to chemotherapy in bone and soft tissue sarcomas.
Iagaru A; Masamed R; Chawla SP; Menendez LR; Fedenko A; Conti PS
Clin Nucl Med; 2008 Jan; 33(1):8-13. PubMed ID: 18097248
[TBL] [Abstract][Full Text] [Related]
12. (18) F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of recurrent bone and soft tissue sarcoma.
Al-Ibraheem A; Buck AK; Benz MR; Rudert M; Beer AJ; Mansour A; Pomykala KL; Haller B; Juenger H; Scheidhauer K; Schwaiger M; Herrmann K
Cancer; 2013 Mar; 119(6):1227-34. PubMed ID: 23233156
[TBL] [Abstract][Full Text] [Related]
13. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors.
Gayed I; Vu T; Iyer R; Johnson M; Macapinlac H; Swanston N; Podoloff D
J Nucl Med; 2004 Jan; 45(1):17-21. PubMed ID: 14734662
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and patterns of bone metastases detected with positron emission tomography using F-18 FDG.
Nakamoto Y; Osman M; Wahl RL
Clin Nucl Med; 2003 Apr; 28(4):302-7. PubMed ID: 12642709
[TBL] [Abstract][Full Text] [Related]
15. FDG-PET for evaluating musculoskeletal tumors: a review.
Aoki J; Endo K; Watanabe H; Shinozaki T; Yanagawa T; Ahmed AR; Takagishi K
J Orthop Sci; 2003; 8(3):435-41. PubMed ID: 12768492
[TBL] [Abstract][Full Text] [Related]
16. Clinical value of [18-F]] fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas.
Schwarzbach MH; Dimitrakopoulou-Strauss A; Willeke F; Hinz U; Strauss LG; Zhang YM; Mechtersheimer G; Attigah N; Lehnert T; Herfarth C
Ann Surg; 2000 Mar; 231(3):380-6. PubMed ID: 10714631
[TBL] [Abstract][Full Text] [Related]
17. Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients.
Kushner BH; Yeung HW; Larson SM; Kramer K; Cheung NK
J Clin Oncol; 2001 Jul; 19(14):3397-405. PubMed ID: 11454888
[TBL] [Abstract][Full Text] [Related]
18. Comparison and discrepancy of 18F-2-deoxyglucose positron emission tomography and Tc-99m MDP bone scan to detect bone metastases.
Kao CH; Hsieh JF; Tsai SC; Ho YJ; Yen RF
Anticancer Res; 2000; 20(3B):2189-92. PubMed ID: 10928175
[TBL] [Abstract][Full Text] [Related]
19. [Correlation of FDG-PET and MRI/CT with histopathology in primary diagnosis, lymph node staging and diagnosis of recurrency of head and neck cancer].
Pöpperl G; Lang S; Dagdelen O; Jäger L; Tiling R; Hahn K; Tatsch K
Rofo; 2002 Jun; 174(6):714-20. PubMed ID: 12063600
[TBL] [Abstract][Full Text] [Related]
20. Whole-body PET with FDG for the diagnosis of recurrent gastric cancer.
De Potter T; Flamen P; Van Cutsem E; Penninckx F; Filez L; Bormans G; Maes A; Mortelmans L
Eur J Nucl Med Mol Imaging; 2002 Apr; 29(4):525-9. PubMed ID: 11914891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
